Table 2.
Patient demographics.
| Healthy adults (HA) | Older adults (OA) | Oncohematologic patients | |||||
|---|---|---|---|---|---|---|---|
| Untreated (UP) | Lenalidomide-treated (LP) | Ibrutinib-treated (IP) | Rituximab-treated (RP) | ||||
| n | 27 | 20 | 7 | 8 | 14 | 10 | |
| Age | 59 (50–63) | 89 (86-94) | 66 (62-70) | 63.5 (56.25-74.75) | 66 (59-71) | 64 (60-73) | |
| Sex (female) | 15 (55.55%) | 18 (90%) | 5 (71.42%) | 5 (62.5%) | 5 (45.45%) | 2 (20%) | |
| Vaccine | BNT162b2 (Pfizer-BioNTech) | 27 | 20 | 1 | – | 2 | 1 |
| mRNA-1273 (Moderna) | – | – | 6 | 8 | 12 | 9 | |
| Oncohematologic disease | Chronic lymphocytic leukemia (CLL) | – | – | 5 | – | 14 | – |
| Follicular Lymphoma (FL) | – | – | 2 | – | – | – | |
| non-Hodgkin’s Lymphoma | – | – | – | – | – | 10 | |
| Myeloma | – | – | – | 8 | – | – | |
| Treatment | No treatment | – | – | 7 | – | – | – |
| Lenalidomide | – | – | – | 8 | – | – | |
| Ibrutinib | – | – | – | – | 14 | – | |
| Rituximab | – | – | – | – | – | 10 | |
| SARS-CoV-2 PCR+ | 7 out of 23 | 3 out of 20 | 1 out of 7 | 2 out of 7 | 9 out of 13 | 2 out of 7 | |
| COVID-19 Disease (Severe) | 0 out of 7 | 0 out of 3 | 0 out of 1 | 0 out of 2 | 3 out of 9 | 0 out of 1 | |